Angiotensin-(1-9) reverses experimental hypertension and cardiovascular damage by inhibition of the angiotensin converting enzyme/Ang II axis

Journal of Hypertension

Volumn 32, Issue 4, 2014, Pages 771-783

  Ocaranza, Maria Paz ^a   Moya, Jackeline ^a   Barrientos, Victor ^b,c   Alzamora, Rodrigo ^b,c   Hevia, Daniel ^a,d   Morales, Cristobal ^a   Pinto, Melissa ^a   Escudero, Nicolás ^a   García, Lorena ^d   Novoa, Ulises ^a   Ayala, Pedro ^d   Díaz Araya, Guillermo ^d   Godoy, Ivan ^a   Chiong, Mario ^d   Lavandero, Sergio ^d,e   Jalil, Jorge E ^a   Michea, Luis ^b,c  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b Facultad de Medicina Universidad Andrés Bello   (Chile)

^c Facultad de Medicina   (Chile)

^d UNIVERSITY OF CHILE   (Chile)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Angiotensin II; Angiotensin (1'9); Cardiovascular remodeling; Fibrosis; Hypertension; Hypertrophy; Renin'angiotensin system

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN (1 9); ANGIOTENSIN[1-7][7 DEXTRO ALANINE]; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MESSENGER RNA; NITRATE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN I; ANGIOTENSIN I (1-9); ANGIOTENSIN II; IMIDAZOLE DERIVATIVE; PEPTIDE FRAGMENT; PYRIDINE DERIVATIVE; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN DERIVATIVE; ANGIOTENSIN[1-9]; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA WALL; ARTICLE; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG EFFECT; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; ENZYME INHIBITION; EXPERIMENTAL HYPERTENSION; HEART FUNCTION; HEART LEFT VENTRICLE; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; MALE; MESENTERIC ARTERY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING; ANIMAL; AORTA; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; HEART VENTRICLE; HEMODYNAMICS; PATHOLOGY; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; VASCULAR ENDOTHELIUM; ARTERY CLAMP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY ARTERY; RADIOIMMUNOASSAY;

ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; AORTA; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; ENDOTHELIUM, VASCULAR; HEART VENTRICLES; HEMODYNAMICS; HYPERTENSION; IMIDAZOLES; MALE; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84896315328     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000094     Document Type: Article

References (48)

1. Ferrario CM. Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research. J Renin Angiotensin Aldosterone Syst 2006; 7:3-14
2. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87:E1-E9
3. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, De Buhr I, et al. Angiotensin-(1-7) is an endogenous ligand for the G proteincoupled receptor Mas. Proc Natl Acad Sci U S A 2003; 100:8258-8263
4. Erdos EG, Jackman HL, Brovkovych V, Tan F, Deddish PA. Products of angiotensin I hydrolysis by human cardiac enzymes potentiate bradykinin. J Mol Cell Cardiol 2002; 34:1569-1576
5. Warner FJ, Smith AI, Hooper NM, Turner AJ. Angiotensin-converting enzyme-2: A molecular and cellular perspective. Cell Mol Life Sci 2004; 61:2704-2713
6. Drummer OH, Kourtis S, Johnson H. Formation of angiotensin II and other angiotensin peptides from des-leu 10-angiotensin I in rat lung and kidney. Biochem Pharmacol 1988; 37:4327-4333
7. Johnson H, Kourtis S, Waters J, Drummer OH. Radioimmunoassay for immunoreactive [des-Leu10]-angiotensin I. Peptides 1989; 1:489-492
8. Ocaranza MP, Godoy I, Jalil JE, Varas M, Collantes P, Pinto M, et al. Enalapril attenuates downregulation of Angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat. Hypertension 2006; 48:572-578
9. Flores-Munoz M, Smith NJ, Haggerty C, Milligan G, Nicklin SA. Angiotensin1-9 antagonises pro-hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptor. J Physiol 2011; 589:939-951
10. Flores-Munoz M, Work LM, Douglas K, Denby L, Dominiczak AF, Graham D, et al. Angiotensin-(1-9) attenuates cardiac fibrosis in the stroke-prone spontaneously hypertensive rat via the angiotensin type 2 receptor. Hypertension 2012; 59:300-307
11. Ocaranza MP, Lavandero S, Jalil JE, Moya J, Pinto M, Novoa U, et al. Angiotensin-(1-9) regulates cardiac hypertrophy in vivo and in vitro. J Hypertens 2010; 28:1054-1064
12. Ocaranza MP, Piddo AM, Faundez P, Lavandero S, Jalil JE. Angiotensin I-converting enzyme gene polymorphism influences chronic hypertensive response in the rat Goldblatt model. J Hypertens 2002; 20:413-420
13. McCarthy CA, Vinh A, Callaway JK, Widdop RE. Angiotensin AT2 receptor stimulation causes neuroprotection in a conscious rat model of stroke. Stroke 2009; 40:1482-1489
14. Cipolla MJ, Smith J, Bishop N, Bullinger LV, Godfrey JA. Pregnancy reverses hypertensive remodeling of cerebral arteries. Hypertension 2008; 51:1052-1057
15. Igase M, Strawn WB, Gallagher PE, Geary RL, Ferrario CM. Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2005; 289:H1013-H1019
16. Ocaranza MP, Rivera P, Novoa U, Pinto M, Gonzalez L, Chiong M, et al. Rho kinase inhibition activates the homologous angiotensin-converting enzyme-angiotensin-(1-9) axis in experimental hypertension. J Hypertens 2011; 29:706-715
17. Campbell DJ, Kladis A, Duncan AM. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 1994; 23:439-449
18. Ocaranza MP, Diaz-Araya G, Carreno JE, Munoz D, Riveros JP, Jalil JE, et al. Polymorphism in gene coding for ACE determines different development of myocardial fibrosis in rats. Am J Physiol Heart Circ Physiol 2004; 286:H498-H506
19. Rivera P, Ocaranza MP, Lavandero S, Jalil JE. Rho kinase activation and gene expression related to vascular remodeling in normotensive rats with high angiotensin I converting enzyme levels. Hypertension 2007; 50:792-798
20. Jalil JE, Perez A, Ocaranza MP, Bargetto J, Galaz A, Lavandero S. Increased aortic NADPH oxidase activity in rats with genetically high angiotensin-converting enzyme levels. Hypertension 2005; 46:1362-1367
21. Friedberg MA, Hinsdale ME, Shihabi ZK. Analysis of nitrate in biological fluids by capillary electrophoresis. J Chromatogr A 1997; 781: 491-496
22. Perez FR, Venegas F, Gonzalez M, Andres S, Vallejos C, Riquelme G, et al. Endothelial epithelial sodium channel inhibition activates endothelial nitric oxide synthase via phosphoinositide 3-kinase/Akt in small-diameter mesenteric arteries. Hypertension 2009; 53:1000-1007
23. Michea L, Delpiano AM, Hitschfeld C, Lobos L, Lavandero S, Marusic ET. Eplerenone blocks nongenomic effects of aldosterone on the Na/ H exchanger, intracellular Ca2 levels, and vasoconstriction in mesenteric resistance vessels. Endocrinology 2005; 146:973-980
24. Aranguiz-Urroz P, Canales J, Copaja M, Troncoso R, Vicencio JM, Carrillo C, et al. Beta (2)-adrenergic receptor regulates cardiac fibroblast autophagy and collagen degradation. Biochim Biophys Acta 2011; 1812:23-31
25. Catalan M, Smolic C, Contreras A, Ayala P, Olmedo I, Copaja M, et al. Differential regulation of collagen secretion by kinin receptors in cardiac fibroblasts and myofibroblasts. Toxicol Appl Pharmacol 2012; 261:300-308
26. Widdop RE, Matrougui K, Levy BI, Henrion D. AT2 receptor-mediated relaxation is preserved after long-term AT1 receptor blockade. Hypertension 2002; 40:516-520
27. Abadir PM, Periasamy A, Carey RM, Siragy HM. Angiotensin II type 2 receptor-bradykinin B2 receptor functional heterodimerization. Hypertension 2006; 48:316-322
28. Abadir PM, Carey RM, Siragy HM. Angiotensin AT2 receptors directly stimulate renal nitric oxide in bradykinin B2-receptor-null mice. Hypertension 2003; 42:600-604
29. Bosnyak S, Jones ES, Christopoulos A, Aguilar M-I, Thomas WG, Widdop RE. Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. Clin Sci 2011; 121:297-303
30. De Gasparo M, Catt KJ, Inagami I, Wright JW, Unger TH. International Union of Pharmacology XXIII The angiotensin II receptors. Pharmacol Rev 2000; 52:415-472
31. Whitebread S, Mele M, Kamber B, De Gasparo M. Preliminary biochemical characterization of two angiotensin II receptor subtypes. Biochem Biophys Res Commun 1989; 163:284-291
32. Bouley R, Perodin J, Plante H, Rihakova L, Bernier SG, Maletinska L, et al. N- and C-terminal structure-activity study of angiotensin II on the angiotensin AT2 receptor. Eur J Pharmacol 1998; 343:323-331
33. Mukoyama M, Horiuchi M, Nakajima M, Pratt RE, Dzau VJ. Characterization of a rat type-2 angiotensin-II receptor stably expressed in 293 cells. Mol Cell Endocrinol 1995; 112:61-68
34. Timmermans PB, Wong PC, Chiu AT, Herblin WF. Nonpeptide angiotensin II receptor antagonists. Trends Pharmacol Sci 1991; 12:55-62
35. Price RL, Carver W, Simpson DG, Fu L, Zhao J, Borg TK, et al. The effects of angiotensin II and specific angiotensin receptor blockers on embryonic cardiac development and looping patterns. Dev Biol 1997; 192:572-584
36. Velazquez-Armenta EY, Han JY, Choi JS, Yang KM, Nava-Ocampo AA. Angiotensin II receptor blockers in pregnancy: A case report and systematic review of the literature. Hypertens Pregnancy 2007; 26:51-66
37. Biermann D, Heilmann A, Didie M, Schlossarek S, Wahab A, Grimm M, et al. Impact of AT2 receptor deficiency on postnatal cardiovascular development. PLoS ONE 2012; 7:e47916. doi 10.1371
38. Ichiki T, Labosky PA, Shiota C, Okuyama S, Imagawa Y, Fogo A, et al. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 1995; 377:748-750
39. Metcalfe BL, Huentelman MJ, Parilak LD, Taylor DG, Katovich MJ, Knot HJ, et al. Prevention of cardiac hypertrophy by angiotensin II type-2 receptor gene transfer. Hypertension 2004; 43:1233-1238
40. Gao L, Wang W, Wang W, Li H, Sumners C, Zucker I. Effects of angiotensin type 2 receptor overexpression in the rostral ventrolateral medulla on blood pressure. Hypertension 2008; 51:521-527
41. Tsutsumi Y, Matsubara H, Masaki H, Kurihara H, Murasawa S, Takai S, et al. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 1999; 104:925-935
42. Carey RM, Howell NL, Jin XH, Siragy HM. Angiotensin type 2 receptormediated hypotension in angiotensin type-1 receptor-blocked rats. Hypertension 2001; 38:1272-1277
43. Bosnyak S, Welungoda IK, Hallberg A, Alterman M, Widdop RE, Jones ES. Stimulation of angiotensin AT2 receptors by the nonpeptide agonist, Compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats. Br J Pharmacol 2010; 159:709-716
44. Siragy HM. The angiotensin II type 2 receptor and the kidney. J Renin Angiotensin Aldosterone System 2010; 11:33-36
45. Obst M, Gross V, Janke J, Wellner M, Schneider W, Luft FC. Pressure natriuresis in AT2 receptor-deficient mice with L-NAME hypertension. J Am Soc Nephrol 2003; 14:303-310
46. Hakam AC, Hussain T. Angiotensin II AT2 receptors inhibit proximal tubular Na-K-ATPase activity via a NO/cGMP-dependent pathway. Am J Physiol Renal Physiol 2006; 290:F1430-F1436
47. Jackman HL, Massad MG, Sekosan M, Tan F, Brovkovych V, Marcic BM, et al. Angiotensin 1-9 and 1-7 release in human heart: Role of cathepsin A. Hypertension 2002; 39:976-981
48. D'Amore A, Black MJ, Thomas WG. The angiotensin II type 2 receptor causes constitutive growth of cardiomyocytes and does not antagonize angiotensin II type 1 receptor-mediated hypertrophy. Hypertension 2005; 46:1347-1354